Literature DB >> 9349513

A more accurate measure of the false-negative rate of Papanicolaou smear screening is obtained by determining the false-negative rate of the rescreening process.

A A Renshaw1, S A DiNisco, L J Minter, E S Cibas.   

Abstract

BACKGROUND: The false-negative rate (FNR), or fraction, of Papanicolaou (Pap) smear screening has been proposed as a useful quality assessment measure. The FNR should account for the FNR of the rescreening process itself. The authors measured the FNR of the rescreening process by rescreening a set of abnormal smears.
METHODS: A randomly selected group of negative (150) and abnormal (91) smears were rescreened in a blinded fashion. A diagnosis of atypical squamous cells of undetermined significance (ASCUS) or worse was used as a positive (abnormal) result. All discrepancies were confirmed by consensus review. The true FNR of screening Pap smears was calculated as: true FNR = calculated FNR/(1-FNR of rescreening).
RESULTS: When rescreened, 17 originally negative cases were interpreted as ASCUS and 5 as unsatisfactory. Twenty-three originally abnormal cases (22 ASCUS and 1 low grade squamous intraepithelial lesion) were interpreted as negative. After consensus review, only 1 of the originally negative cases was believed to be ASCUS and 1 unsatisfactory; 18 of the 23 originally abnormal cases were believed to be rescreening errors and 5 of the 23 originally abnormal cases were believed to be false-positives. The FNR of Pap smear screening as traditionally calculated was 6.1%, which was slightly less than the laboratory's usual FNR. The FNR of review screening was 20.9%. The true FNR of Pap smear screening was 7.8% and the false-positive rate was 0.6%.
CONCLUSIONS: The FNR of rescreening is not insubstantial. It can and should be measured by rescreening abnormal smears, and when taken into account yields a more accurate measure of the FNR of Pap smear screening.

Entities:  

Mesh:

Year:  1997        PMID: 9349513

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Factors, associated with elevated concentration of soluble carbonic anhydrase IX in plasma of women with cervical dysplasia.

Authors:  Švitrigailė Grincevičienė; Daiva Vaitkienė; Daiva Kanopienė; Rasa Vansevičiūtė; Jan Tykvart; Artūras Sukovas; Joana Celiešiūtė; Ernesta Ivanauskaitė Didžiokienė; Arvydas Čižauskas; Aida Laurinavičienė; Vlastimil Král; Anna Hlavačková; Jitka Zemanová; Dovilė Stravinskienė; Aistė Sližienė; Agnė Petrošiūtė; Vytautas Petrauskas; Renata Balsytė; Jonas Grincevičius; Vaclav Navratil; Ullrich Jahn; Jan Konvalinka; Aurelija Žvirblienė; Daumantas Matulis; Jurgita Matulienė
Journal:  Sci Rep       Date:  2022-09-13       Impact factor: 4.996

2.  Surrogate indicators of sensitivity in gynecologic cytology: can they be used to improve the measurement of sensitivity in the laboratory?

Authors:  Andrew A Renshaw; Fadi Brimo; Manon Auger
Journal:  Cytojournal       Date:  2009-10-09       Impact factor: 2.091

3.  Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL.

Authors:  Prakash K Bhuyan; Michael Dallas; Kim Kraynyak; Timothy Herring; Matthew Morrow; Jean Boyer; Susan Duff; Joseph Kim; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2020-11-11       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.